BCM
CDLX icon

Brooktree Capital Management’s Cardlytics CDLX Stock Holding History

Brooktree Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,225
Closed -$399K – 43
2025
Q2 		$399K Buy
24,225
+1,862
+8% +$32.2K 0.26% 29
2025
Q1 		$407K Buy
22,363
+4,842
+28% +$138K 0.31% 22
2024
Q4 		$650K Buy
17,521
+757
+5% +$29K 0.48% 21
2024
Q3 		$536K Buy
16,764
+3,317
+25% +$184K 0.44% 23
2024
Q2 		$1.1M Sell
13,447
-450
-3% -$48.7K 0.94% 21
2024
Q1 		$2.01M Buy
13,897
+2,115
+18% +$179K 1.55% 18
2023
Q4 		$1.09M Sell
11,782
-142
-1% -$14.4K 0.88% 22
2023
Q3 		$1.97M Sell
11,924
-122
-1% -$15.8K 1.64% 19
2023
Q2 		$761K Buy
12,046
+360
+3% +$21.8K 0.58% 23
2023
Q1 		$397K Buy
11,686
+7,559
+183% +$395K 0.31% 27
2022
Q4 		$239K Sell
4,127
-5,525
-57% -$341K 0.2% 31
2022
Q3 		$907K Buy
9,652
+6,249
+184% +$889K 0.75% 25
2022
Q2 		$759K Buy
3,403
+1,539
+83% +$515K 0.57% 30
2022
Q1 		$1.02M Buy
+1,864
New +$1.13M 0.67% 32

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Brooktree Capital Management's CDLX Position: Q3 2025 in Review

Brooktree Capital Management sold out of Cardlytics (CDLX) in Q3 2025, closing a stake of 24,225 shares — an estimated $399K sold.

Brooktree Capital Management first reported a position in CDLX in Q1 2022 and held it in 14 quarters. The position peaked at $2.01M in Q1 2024. 81 funds tracked by Wall St. Rank hold CDLX as of Q3 2025.

  • Brooktree Capital Management reported no remaining Cardlytics position as of Q3 2025 after selling out during the quarter.
  • Brooktree Capital Management sold 24,225 Cardlytics shares in Q3 2025, an estimated $399K.
  • Brooktree Capital Management first reported a position in Cardlytics in Q1 2022 and held it in 14 quarters.
  • Brooktree Capital Management's Cardlytics position peaked at $2.01M in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Cardlytics as of Q3 2025.

Based on Brooktree Capital Management's 13F filing for Q3 2025, filed 7 Nov 2025.